ClinicalTrials.gg
Not yet recruitingNCT07874984Updated Oct 15, 2026

SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of SSGJ-706 and SPGL008 in Non Small Cell Lung Cancer, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer. The objective is to evaluate the safety and efficacy of SPGL008 combined with SSGJ-706 in participants with driver gene-negative advanced non-small cell lung cancer.

02

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Non Small Cell Lung Cancer
  • PD-1/PD-L1
  • B7-H3
  • IL-15
03

In context

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

This study's planned enrollment of 220 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and/or females over age 18-75
  2. and/or cytologically documented local advanced or NSCLC .
  3. (ECOG) performance status of 0-1.
  4. Expected survival >=3 months.
  5. Adequate organ or bone marrow function.
  6. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Known positive driver genes
  2. Pregnant or breast-feeding woman.
  3. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria
  4. Known allergies, , or intolerance to SSGJ-706/SPGL008 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    SPGL0008 dose1/2+SSGJ-706 selected dose

    Biological: SSGJ-706 · Biological: SPGL008

  • Experimental
    SPGL0008 selected dose+SSGJ-706 selected dose

    Biological: SSGJ-706 · Biological: SPGL008

  • Experimental
    SPGL0008 selected dose+SSGJ-706 selected dose+chemotherapy

    Biological: SSGJ-706 · Biological: SPGL008 · Drug: Chemotherapy

Interventions

  • BiologicalSSGJ-706

    SSGJ-706 is a bispecific antibody that targets both human PD-1 and PD-L1

  • BiologicalSPGL008

    SPGL008 is a dual-functional molecule that combines an anti-B7-H3 monoclonal antibody with IL-15Rα sushi / IL-15.

  • DrugChemotherapy

    Chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events(AEs) assessed by NCI-CTCAE v6.0

    Collect and analyze the incidence of adverse events to evaluate safety and tolerability per NCI-CTCAE v6.0

    Time frame: 24 months

  2. Objective Response Rate(ORR)

    The efficacy of solid tumors was evaluated according to RECIST v1.1

    Time frame: 24 months

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Collect blood samples at the preset time points, measure the concentrations, draw the concentration-time curve, and select the highest point on the curve.

    Time frame: 24 months

  2. Area under the curve (AUC)

    Based on the concentrations at multiple time points and the time

    Time frame: 24months

  3. Half-life (T1/2)

    Calculate the half-life based on the concentration of the collected data.

    Time frame: 24months

  4. Lymphocytes

    Calculate and analyze the relationship between lymphocytes and efficacy

    Time frame: 24months

  5. Immunogenicity

    Subjects will be tested for anti-drug antibody (ADA), and ADA-positive serum samples will continue to be tested for neutralizing antibodies (NAb).

    Time frame: 24months

  6. Cytokines

    Calculate and analyze the relationship between cytokines and efficacy

    Time frame: 24months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Oct 15, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874984
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

LIN WU
Contact
wulin-calf@vip.163.com
86+13170419973

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SSGJ-706 · SPGL008

Start the discussion